BioSpace News Archive

New Preclinical Repeat-Dose Data Support Company Plans to Evaluate Multiple Ascending Dose Levels in MONARCH, Subject to FDA Review

Orthofix Medical Inc., a global medical device company with a spine and extremities focus, announced the launch of its new O-GENESIS™ Graft Delivery System during the North American Spine Society 2020 virtual annual meeting.

CheckMate -816 met a primary endpoint of improved pathologic complete response in patients who received Opdivo plus chemotherapy before surgery

Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it has been invited to present at the MicroCap Rodeo Best Ideas Bowl, which is being held virtually on October 13th – 16th, 2020.

Janpix Inc., a biotechnology company developing monovalent small molecule protein degraders of STAT proteins as novel therapeutics, today announced the closing of a $10 Million Series B financing.

Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application for APR-548 to treat TP53 mutant myelodysplastic syndromes (MDS)

In a continuing effort to provide the facts about ID NOW to support public health interests, Abbott (NYSE: ABT) is sharing new interim clinical data results on its ID NOW COVID-19 rapid test.

Bristol Myers Squibb announced today that Health Canada approved ZEPOSIA® (ozanimod) for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) to decrease the frequency of clinical exacerbations

Evofem Biosciences, Inc., (NASDAQ: EVFM) announced today that new clinical trial data on Phexxi™ (lactic acid, citric acid and potassium bitartrate) and EVO100 are being discussed in oral and poster presentations at major medical society meetings this month.

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced a coverage update for its novel ZILXI™ (minocycline) topical foam, 1.5%.